Last reviewed 2026-06-01 · How we verify

Exposure to Ergot

Assistance Publique Hopitaux De Marseille · Phase 2 active Small molecule ✓ Verified Jun 2026

Exposure to Ergot is a Small molecule drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 2 development.

Exposure to Ergot has been studied in relation to Migraine treatment, as seen in clinical trials such as NCT02838537. However, Ergot's mechanism of action is not related to Migraine treatment, as it is classified as a VACCINE ANTIGEN and is used as a component of vaccines, such as the Neisseria meningitidis group A and C capsular polysaccharide tetanus toxoid conjugate antigen.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Exposure to Ergot
Sponsor	Assistance Publique Hopitaux De Marseille
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

TRiptan Use and Serious Vascular Events in Elderly Over 65 Years

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Exposure to Ergot CI brief — competitive landscape report
Exposure to Ergot updates RSS · CI watch RSS
Assistance Publique Hopitaux De Marseille portfolio CI

Frequently asked questions about Exposure to Ergot

What is Exposure to Ergot?

Exposure to Ergot is a Small molecule drug developed by Assistance Publique Hopitaux De Marseille.

Who makes Exposure to Ergot?

Exposure to Ergot is developed by Assistance Publique Hopitaux De Marseille (see full Assistance Publique Hopitaux De Marseille pipeline at /company/assistance-publique-hopitaux-de-marseille).

What development phase is Exposure to Ergot in?

Exposure to Ergot is in Phase 2.

Manufacturer: Assistance Publique Hopitaux De Marseille — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing